MétaCan
Menu
Back to cohort
Record W3127156187 · doi:10.1111/ejh.13596

The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma

2021· article· en· W3127156187 on OpenAlexaffabout
Hannah Cherniawsky, Vishal Kukreti, Donna Reece, Esther Masih‐Khan, Arleigh McCurdy, Victor H. Jimenez‐Zepeda, Michaël Sébag, Kevin Song, Darrell White, Julie Stakiw, Richard LeBlanc, Tony Reiman, Martha Louzada, Muhammad Aslam, Rami Kotb, Engin Gul, Eshetu G. Atenafu, Christopher P. Venner

Bibliographic record

VenueEuropean Journal Of Haematology · 2021
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsHôpital Maisonneuve-RosemontUniversité de MontréalUniversity of SaskatchewanDalhousie UniversityUniversity of CalgaryPrincess Margaret Cancer CentreVancouver General HospitalInstitute of Cancer ResearchSaint John Regional HospitalBC Cancer AgencyCancerCare ManitobaOccupational Cancer Research CentreOttawa HospitalCanadian Institutes of Health ResearchMcGill UniversityQueen Elizabeth II Health Sciences CentreUniversity of Alberta
Fundersnot available
KeywordsLenalidomideMedicineMultiple myelomaInternal medicineOncologyCohortMaintenance therapyThalidomideChemotherapySurgery

Abstract

fetched live from OpenAlex

OBJECTIVES: To understand the impact of therapy sequencing on progression-free (PFS) and overall survival (OS) for the treatment of multiple myeloma (MM). The use of daily, low-dose, lenalidomide maintenance (LM) has raised concern for fostering resistance, preventing its use in the relapsed setting. METHODS: We conducted a retrospective analysis of survival outcomes from the Canadian Myeloma Research Group Database. Patients were grouped based on receipt of LM after autologous stem cell transplant and receipt of lenalidomide in second-line therapy, 575 patients were included. RESULTS: Patients treated with LM had statistically similar 2nd PFS when re-exposed to lenalidomide in second-line therapy compared to those receiving non-lenalidomide-containing regimens (10.2 vs 14.0 months, P =.53). This cohort also had the longest 2nd OS, 18 months longer than patients treated with LM who did not receive lenalidomide at relapse (55.3 vs 37 months, P =.004). Patients treated with LM also demonstrated deeper responses to second-line therapy than their non-LM counterparts. CONCLUSION: Our data suggest that patients progressing on LM who receive lenalidomide-containing therapy at first relapse have comparable 2nd PFS and better 2nd OS compared to non-lenalidomide-containing second-line regimens. Identification of patients mostly likely to benefit from further lenalidomide-containing therapy is paramount.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.029
Threshold uncertainty score0.308

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.285
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueEuropean Journal Of HaematologySame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207